A New Frontier in Immuno-Oncology
Targeting intractable immune pathways in the tumor microenvironment
Management Team
President, CEO, and Cofounder
Vice President Research and Cofounder
Chief Medical Advisor
Head of Operations
Scientific Advisory Board
Greg Barton, Ph.D.
Samuel Miller, M.D.
Denise Monack, Ph.D.
Paul Rennert, Ph.D.
Mario Sznol, M.D.
Clinical Advisory Board
Joel Randolph Hecht, M.D.
Jason Luke, M.D.
Mario Sznol, M.D.
News
BERKELEY, Calif., April 27, 2020
Financing will fund Actym’s cancer immunotherapy pipeline into clinical development
BERKELEY, Calif., Nov 7, 2019 PRNewswire
The presentation will highlight Actym’s novel tumor-specific therapies that deliver multiplexed immunomodulatory payloads after systemic administration.
BERKELEY, Calif., April 10, 2019
Actym Therapeutics announced that Dr. Christopher Thanos, President, CEO, and Cofounder, has been invited to speak at the 15th annual PEGS Conference in Boston, MA.
Apr 02, 2019 PRNewswire
Two presentations will highlight Actym's novel IV administered, tumor-infiltrating therapies that express immuno-modulatory factors
Nov 8, 2018 PRNewswire
Presentation will focus on a novel tumor-targeting, systemically-delivered STING pathway agonist that demonstrates robust anti-tumor efficacy in multiple murine cancer models.
